# A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

> **NCT00902681** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 36 (estimated)

## Conditions studied

- Treatment of Overactive Bladder

## Interventions

- **DRUG:** Fesoterodine
- **DRUG:** Fesoterodine

## Key facts

- **NCT ID:** NCT00902681
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902681, "A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00902681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*